Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 1/2017

01-02-2017 | ORIGINAL ARTICLE

Mangiferin Inhibits IL-1β-Induced Inflammatory Response by Activating PPAR-γ in Human Osteoarthritis Chondrocytes

Authors: Yanlong Qu, Li Zhou, Chunlei Wang

Published in: Inflammation | Issue 1/2017

Login to get access

Abstract

Inflammation has been reported to play critical roles in the development of osteoarthritis. In the present study, we investigated whether mangiferin (MFN) had anti-inflammatory effects in IL-1β-stimulated human osteoarthritis chondrocytes. The cells were treated with various concentrations of MFN in the presence or absence of IL-1β. The production of MMP-1, MMP-3, PGE2, and NO was measured in this study. The expression of NF-kB and PPAR-γ was detected by western blot analysis. MFN inhibited IL-1β-induced inflammatory mediators PGE2 and NO production. MFN also inhibited IL-1β-induced MMP1 and MMP3 production. IL-1β-induced NF-kB activation was significantly inhibited by MFN. In addition, MFN was found to up-regulate the expression of PPAR-γ in human osteoarthritis chondrocytes. PPAR-γ inhibitor GW9662 significantly reversed the anti-inflammatory effects of MFN. These results suggest that MFN inhibits IL-1β-induced inflammatory response in human osteoarthritis chondrocytes by activating PPAR-γ.
Literature
1.
Martin, J.A., and J.A. Buckwalter. 2002. Aging, articular cartilage chondrocyte senescence and osteoarthritis. Biogerontology 3: 257–264.CrossRefPubMed
2.
Bonnet, C., and D. Walsh. 2005. Osteoarthritis, angiogenesis and inflammation. Rheumatology 44: 7–16.CrossRefPubMed
3.
Van der Kraan, P., and W. Van den Berg. 2012. Chondrocyte hypertrophy and osteoarthritis: Role in initiation and progression of cartilage degeneration? Osteoarthritis and Cartilage 20: 223–232.CrossRefPubMed
4.
Abramson, S.B., M. Attur, A.R. Amin, and R. Clancy. 2001. Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis. Current Rheumatology Reports 3: 535–541.CrossRefPubMed
5.
Ahmed, S., A. Rahman, A. Hasnain, M. Lalonde, V.M. Goldberg, and T.M. Haqqi. 2002. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1β-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radical Biology and Medicine 33: 1097–1105.CrossRefPubMed
6.
7.
Roman-Blas, J., and S. Jimenez. 2006. NF-kB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis and Cartilage 14: 839–848.CrossRefPubMed
8.
Chen, Y.-C., L.-L. Yang, and T.J. Lee. 2000. Oroxylin A inhibition of lipopolysaccharide-induced iNOS and COX-2 gene expression via suppression of nuclear factor-kB activation. Biochemical Pharmacology 59: 1445–1457.CrossRefPubMed
9.
Bhatia, H.S., E. Candelario-Jalil, A.C. de Oliveira, O.A. Olajide, G. Martinez-Sanchez, and B.L. Fiebich. 2008. Mangiferin inhibits cyclooxygenase-2 expression and prostaglandin E2 production in activated rat microglial cells. Archives of Biochemistry and Biophysics 477: 253–258.CrossRefPubMed
10.
Jang, J.H., K.H. Lee, H.K. Jung, M.O. Sim, T.M. Kim, K.W. Woo, B.K. An, J.H. Cho, and H.W. Cho. 2016. Anti-inflammatory effects of 6′-O-acetyl mangiferin from Iris rossii Baker via NF-kappab signal blocking in lipopolysaccharide-stimulated RAW 264.7 cells. Chemico-Biological Interactions 257: 54–60.CrossRefPubMed
11.
Pan, C.W., Z.Z. Pan, J.J. Hu, W.L. Chen, G.Y. Zhou, W. Lin, L.X. Jin, and C.L. Xu. 2016. Mangiferin alleviates lipopolysaccharide and D-galactosamine-induced acute liver injury by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation. European Journal of Pharmacology 770: 85–91.CrossRefPubMed
12.
He, L., X. Peng, J. Zhu, X. Chen, H. Liu, C. Tang, Z. Dong, F. Liu, and Y. Peng. 2014. Mangiferin attenuate sepsis-induced acute kidney injury via antioxidant and anti-inflammatory effects. American Journal of Nephrology 40: 441–450.CrossRefPubMed
13.
Dou, W., J. Zhang, G. Ren, L. Ding, A. Sun, C. Deng, X. Wu, X. Wei, S. Mani, and Z. Wang. 2014. Mangiferin attenuates the symptoms of dextran sulfate sodium-induced colitis in mice via NF-kappaB and MAPK signaling inactivation. International Immunopharmacology 23: 170–178.CrossRefPubMedPubMedCentral
14.
Cheng, A.W., T.V. Stabler, M. Bolognesi, and V.B. Kraus. 2011. Selenomethionine inhibits IL-1beta inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX2) expression in primary human chondrocytes. Osteoarthritis and Cartilage 19: 118–125.CrossRefPubMed
15.
Ma, C., Y. Zhang, Y.Q. Li, C. Chen, W. Cai, and Y.L. Zeng. 2015. The role of PPARgamma in advanced glycation end products-induced inflammatory response in human chondrocytes. PLoS One 10, e0125776.CrossRefPubMedPubMedCentral
16.
Piao, T., Z. Ma, X. Li, and J. Liu. 2015. Taraxasterol inhibits IL-1beta-induced inflammatory response in human osteoarthritic chondrocytes. European Journal of Pharmacology 756: 38–42.CrossRefPubMed
17.
Goldring, S.R., and M.B. Goldring. 2004. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clinical Orthopaedics and Related Research 427: S27–S36.CrossRef
18.
Braissant, O., F. Foufelle, C. Scotto, M. Dauca, and W. Wahli. 1996. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137: 354–366.PubMed
19.
Park, K.S. 2016. Catalpol reduces the production of inflammatory mediators via PPAR-gamma activation in human intestinal Caco-2 cells. Journal of Natural Medicines 70: 620–626.CrossRefPubMed
20.
Chang, C.Z., S.C. Wu, and A.L. Kwan. 2015. Glycyrrhizin attenuates proinflammatory cytokines through a peroxisome proliferator-activated receptor-gamma-dependent mechanism and experimental vasospasm in a rat model. Journal of Vascular Research 52: 12–21.CrossRefPubMed
21.
Bo, Q.L., Y.H. Chen, Z. Yu, L. Fu, Y. Zhou, G.B. Zhang, H. Wang, Z.H. Zhang, and D.X. Xu. 2016. Rosiglitazone pretreatment protects against lipopolysaccharide-induced fetal demise through inhibiting placental inflammation. Molecular and Cellular Endocrinology 423: 51–59.CrossRefPubMed
22.
Song, Y., H.F. Zhao, J.Y. Liu, C. Fang, and R.Y. Miao. 2016. Effects of citral on lipopolysaccharide-induced inflammation in human umbilical vein endothelial cells. Inflammation 39: 663–671.CrossRefPubMed
Metadata
Title
Mangiferin Inhibits IL-1β-Induced Inflammatory Response by Activating PPAR-γ in Human Osteoarthritis Chondrocytes
Authors
Yanlong Qu
Li Zhou
Chunlei Wang
Publication date
01-02-2017
Publisher
Springer US
Published in
Inflammation / Issue 1/2017
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-016-0451-y

Other articles of this Issue 1/2017

Inflammation 1/2017 Go to the issue

ORIGINAL ARTICLE

Murine Double Minute-2 Inhibition Attenuates Cardiac Dysfunction and Fibrosis by Modulating NF-κB Pathway After Experimental Myocardial Infarction

ORIGINAL ARTICLE

TAZ Activator Is Involved in IL-10-Mediated Muscle Responses in an Animal Model of Traumatic Brain Injury

REVIEW

Foxp3, Regulatory T Cell, and Autoimmune Diseases

ORIGINAL ARTICLE

Immunomodulatory Effects of Adjuvants CPG, MPLA, and BCG on the Derp2-Induced Acute Asthma at Early Life in an Animal Model of BALB/c Mice

ORIGINAL ARTICLE

Effects of CCK-8 and Cystathionine γ-Lyase/Hydrogen Sulfide System on Acute Lung Injury in Rats

ORIGINAL ARTICLE

Intranasal Curcumin Inhibits Pulmonary Fibrosis by Modulating Matrix Metalloproteinase-9 (MMP-9) in Ovalbumin-Induced Chronic Asthma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits